BIMASTAT
ORAL SUSPENSION
Sulfadiazine 150mg/ml - Neomycin 25mg/ml

DATA SHEET



INDICATIONS

For the treatment of diarrhoea in pre-ruminant calves associated with infections caused by organisms known to be, or suspected of being, susceptible to the combination of sulfadiazine and neomycin.

BENEFITS

- **Unique pink formulation for treating calves with susceptible bacterial infections.**
- **Easy oral dose of 4ml per 10kg bodyweight twice a day for up to 5 days.**
- **Contains the antibiotics sulphadiazine and neomycin, plus kaolin.**

LIST No	UNIT PACKAGE	CASE SIZE
1BIM052	250 ml	12
1BIM053	1L	10

See reverse for Administration & Dosage

BIMASTAT
Oral Suspension
Sulfadiazine 150mg/ml - Neomycin 25mg/ml

ACTIVE SUBSTANCES
Sulfadiazine 150.0 mg/ml and Neomycin (as neomycin sulphate) 25.0 mg/ml. Oral suspension.

TARGET SPECIES
Pre-ruminant calves.

INDICATIONS FOR USE
For the treatment of diarrhoea in pre-ruminant calves associated with infections caused by organisms known to be, or suspected of being, susceptible to the combination of sulfadiazine and neomycin.

AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
Administration is by oral drench. Shake well before use.
The recommended dose is:
4 ml per 10 kg bodyweight twice daily. This equates to 60 mg/kg Sulphadiazine, 10 mg/kg Neomycin and 42 mg/kg Kaolin twice daily.
The maximum period of treatment is 5 days. To ensure a correct dosage, bodyweight should be determined as accurately as possible.

WITHDRAWAL PERIOD
Animals intended for human consumption must not be slaughtered during treatment. Calves intended for human consumption may only be slaughtered after 28 days from the last treatment. Not intended for animals producing milk for human consumption.

CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active ingredients. Do not exceed the recommended dosage or the period of treatment. Do not use local anaesthetics of the procaine group during treatment as they are antagonistic to the sulphonamide component. Do not use in calves with functional rumens. Do not use in lactating cows. Do not use in foals and horses.

SPECIAL WARNINGS FOR EACH TARGET SPECIES
Concurrent intravenous fluid therapy should be considered in dehydrated calves. Parenteral antibiotic treatment should be considered if a clinical response is not seen after 48 hours treatment.

SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINE
Avoid contact with skin. Wash hands after use.

ADVERSE REACTIONS
Chronic usage of oral neomycin may result in bacterial or fungal superinfections.

USE DURING PREGNANCY OR LACTATION
The product is intended for use in calves only. Do not use in lactating cows.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONS
There is interaction and antagonism between sulphonamides and the Vitamin B Complex. Do not use local anaesthetics of the procaine group during treatment, as they are antagonistic to the sulphonamide component.

OVERDOSE
Good tolerance has been confirmed in calves at x3 and x5 the recommended dose rate.

PHARMACODYNAMIC PROPERTIES
Pharmacotherapeutic group: Sulfonamides, combinations with other antibacterials.

Sulphadiazine is a broad-spectrum antimicrobial agent. It acts by interfering with the biosynthesis of folic acid in bacterial cells, competitively preventing para-aminobenzoic acid (PABA) from incorporation into the folic acid molecule. It is rapidly absorbed from the gastrointestinal tract and widely distributed to all tissues and body fluids. The sulphonamides are eliminated by a combination of renal excretion and biotransformation.

Neomycin is the isomeric mixture of Neomycin B and C. It has a rapid dose related bactericidal action on susceptible microorganisms. The antibacterial action is directed primarily against aerobic gram-negative bacteria. It is poorly absorbed from the gastrointestinal tract, has a short life and is nearly all excreted unchanged in the faeces.

Kaolin is a standard long-established adsorbent in human and veterinary medicine.

MAJOR INCOMPATIBILITIES
None known.

SHELF-LIFE
Shelf-life of the veterinary medicinal product as packaged for sale: 18 months.

SPECIAL PRECAUTIONS FOR STORAGE
Do not store above 25°C.

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCTS OR WASTE MATERIALS
Any unused product or waste materials should be disposed of in accordance with national requirements.

MARKETING AUTHORISATION HOLDER
Bimeda Animal Health Limited
2, 3 & 4 Airton Close,
Airton Road,
Tallaght,
Dublin 24,
Ireland

MARKETING AUTHORISATION NUMBER
VPA22033/001/001

LEGAL CATEGORY
POM

The product SPC can be found on the HPRA website
Use Medicines Responsibly

TAKE TIME OBSERVE LABEL DIRECTIONS

www.bimeda.ie

Bimeda data sheet created: March 2021